Stockscreener 앱 받기
43.90
0.69%
-0.29
전일 마감가:
$44.19
열려 있는:
$44.23
하루 거래량:
121.15K
Relative Volume:
0.18
시가총액:
$3.13B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-11.11
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
-3.08%
1개월 성능:
+15.15%
6개월 성능:
-15.20%
1년 성능:
-9.25%
1일 변동 폭
$43.34
$45.12
1주일 범위
$43.34
$46.36
52주 변동 폭
$33.19
$61.61
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
43.94 | 3.13B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.98 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.99 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.08 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.22 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
(MRUS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Was Merus N.V (MRUS)’s session last reading good? - uspostnews.com
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus (NASDAQ:MRUS) Position Lifted by Geode Capital Management LLC - Defense World
William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS) - Defense World
Market Watch Highlights: Merus N.V (MRUS) Ends on an Upturn Note at 45.28 - DWinneX
Russell Investments Group Ltd. Decreases Stock Holdings in Merus (NASDAQ:MRUS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merus N.V (MRUS) Is Worth Accumulating At Current Levels - Stocksregister
Daily Progress: Merus N.V (MRUS) Drop -3.19, Closing at 41.83 - DWinneX
MRUS Stock Sees Decline of Approximately -3.22% in Last Five Days - knoxdaily.com
Merus N.V’s Banking’s 100-Day Moving Average at 43.17: Will the Stock Break Through? - investchronicle.com
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO® - GlobeNewswire Inc.
A stock that deserves closer examination: Merus N.V (MRUS) - uspostnews.com
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - The Manila Times
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting | MRUS Stock News - GuruFocus
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting - Nasdaq
Breakthrough Cancer Drug Outperforms Standard Treatment: Phase 2 Trial Shows Superior Survival Rates - Stock Titan
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals | Libero Quotidiano.it - Libero Quotidiano
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Merus N.V (NASDAQ: MRUS): Getting A Free Pass? - stocksregister.com
Merus’ (MRUS) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Raymond James Financial Inc. Invests $347,000 in Merus (NASDAQ:MRUS) - Defense World
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha
KLP Kapitalforvaltning AS Purchases New Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus stock touches 52-week low at $37.76 amid market challenges By Investing.com - Investing.com South Africa
Merus stock touches 52-week low at $37.76 amid market challenges - Investing.com Australia
HighTower Advisors LLC Has $337,000 Position in Merus (NASDAQ:MRUS) - Defense World
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
How To Trade (MRUS) - news.stocktradersdaily.com
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Guggenheim Reiterates “Buy” Rating for Merus (NASDAQ:MRUS) - Defense World
Swiss National Bank Purchases 8,300 Shares of Merus (NASDAQ:MRUS) - Defense World
Merus VP controller Shuman sells $193,990 in common shares By Investing.com - Investing.com India
Merus VP controller Shuman sells $193,990 in common shares - Investing.com
Bank of New York Mellon Corp Sells 1,248 Shares of Merus (NASDAQ:MRUS) - Defense World
Merus (MRUS) Gets a Buy from Citi - The Globe and Mail
US Bancorp DE Lowers Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Given “Buy” Rating at Guggenheim - Defense World
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Given New $70.00 Price Target at Bank of America - Defense World
Why Merus Shares Are Facing Pressure Today - TipRanks
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Mar 21 '25 |
Sale |
48.50 |
4,000 |
193,990 |
11,002 |
| Shuman Harry | VP Controller, PAO |
Jan 01 '25 |
Option Exercise |
0.00 |
5,000 |
0 |
12,002 |
| Lundberg Sven Ante | President, CEO & PEO |
Feb 13 '25 |
Option Exercise |
24.43 |
16,372 |
399,968 |
40,601 |
| Shuman Harry | VP Controller, PAO |
Aug 21 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
0.27%
0.30%
자본화:
|
볼륨(24시간):